Protocol No.: PCYC-1141-CA

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
Principal Investigator
Veltri, Lauren
Phase
III
Age Group
Adult
Applicable Disease Site
Lymphoma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Sylvia McEwuen, RN, CCRC
Study Coordinator/Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov